VERAgene is the only non-invasive prenatal test that can simultaneously screen for aneuploidies, microdeletions and single gene diseases. The diseases screened by VERAgene are associated with moderate severe phenotype with significant impact on the quality of life. By combining detection of aneuploidies and microdeletions with the screening of monogenic disorders, VERAgene provides a comprehensive solution to prospective parents.
The doctor or lab collects biological samples from the pregnant mother and the father. The samples are sent to our state-of-the-art laboratories for analysis. At the laboratory, cell-free DNA is isolated from the mother’s blood and analyzed along with the father’s DNA sample using our proprietary, new generation analytic and bioinformatics tools. Results are provided electronically via a secure portal to your doctor in 4 to 7 working days.